Project Grant R01DE035743
- The National Institute of Dental and Craniofacial Research awarded Duke University $444,125 on September 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate central nervous system and autonomic correlates of temporomandibular disorder pain. The research characterizes how altered brainstem circuit activity and brain glymphatic flow relate to autonomic dysfunction in patients with chronic painful temporomandibular disorder (TMD). The project measures...
- The National Institute of Dental and Craniofacial Research awarded Colorado State University $659,747 on June 18, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to characterize the biomechanical environment of the temporomandibular joint and develop an artificial TMJ disc replacement. The research addresses advanced temporomandibular joint disorders unresponsive to conservative treatment. Current surgical practice removes the diseased disc, but this disrupts joint...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded Columbia University's Health Sciences Division a $655,455 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) effective September 11, 2025, with completion targeted for September 10, 2027. This R01 renewal award supports fundamental and translational research to identify temporomandibular joint (TMJ) cartilage progenitor cells and characterize their...
- The National Institute of Dental and Craniofacial Research awarded Oregon Health & Science University $900,000 on August 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the role of perivascular stromal cells in temporomandibular joint osteoarthritis progression. The research examines how perivascular stem and stromal cells within the temporomandibular joint synovium regulate joint homeostasis and contribute to osteoarthritis severity, with...
- The National Institute of Dental and Craniofacial Research awarded the University of Rochester $111,828 on January 8, 2027, under the Oral Diseases and Disorders Research program (CFDA 93.121) to fund fellowship training in neural circuit research related to temporomandibular joint disorder. The project investigates central nervous system dysfunction underlying temporomandibular joint disorder pathophysiology, specifically testing the hypothesis that alterations in amygdala-brainstem circuitry...
- The National Institute of Dental and Craniofacial Research awarded Massachusetts General Hospital $408,951 on February 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121, R21DE034917) to investigate photochemical tissue passivation as a treatment approach for temporomandibular joint osteoarthritis. The research applies photocrosslinking of tissue proteins—specifically collagen—through rose bengal solution and green light exposure to reduce inflammation and prevent...
- The National Institute of Dental and Craniofacial Research awarded The University of Texas Health Science Center at San Antonio $433,125 on August 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate neuronal-glial coupling mechanisms in temporomandibular joint pain. The project examines the role of connexin 43, a gap junction protein expressed in satellite glial cells, in modulating trigeminal ganglion neuron-glia communication and pain processing in...
- The National Institute of Dental and Craniofacial Research awarded $310,274 to the University of North Carolina at Chapel Hill on August 28, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121). The award funds a multidimensional phenotyping study characterizing the molecular, sensory, and psychosocial factors underlying comorbid temporomandibular disorder and migraine in adolescents. The project recruits 140 youth aged 10 to 17 years with TMD myalgia, stratified by the...
- The National Institute of Dental and Craniofacial Research awarded $1.368593 million to The Regents of the University of California, San Francisco on July 15, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate aberrant mechano-oxygen coupling as a driver of zinc-enriched ectopic mineralization in osteoarthritis. The research integrates complementary expertise across three principal investigators. Longitudinal studies in rats with overloaded...
- The National Institute of Dental and Craniofacial Research, part of the Department of Health and Human Services National Institutes of Health, awarded $315,000 to the University of California, Los Angeles on July 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate bone morphogenetic protein (BMP)-dependent mechanisms underlying mandibular outgrowth and to resolve molecular pathways disrupted in micrognathia, a congenital anomaly affecting mandibular...
The National Institute of Dental and Craniofacial Research awarded the University of Washington $623,593 on September 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121) to investigate the role of P75 neurotrophin receptor (P75NTR) in temporomandibular joint (TMJ) cartilage homeostasis and degenerative disease. The research defines cellular and molecular mechanisms regulating TMJ cartilage health and degeneration, with the goal of developing novel therapeutic strategies for degenerative TMJ disorders. The project uses lineage-specific deletion models in mice to examine the effects of P75NTR deletion on TMJ development and remodeling, investigates how P75NTR signaling disruption affects TMJ pathology in clinically relevant degeneration models, and evaluates the therapeutic potential of engineered P75NTR approaches. Prior findings demonstrate that P75NTR expression is 15-fold higher in TMJ cartilage than in long bone cartilage and significantly reduced in cartilage from TMJ osteoarthritis patients, suggesting a critical role in homeostasis. P75NTR signaling disruption in mouse models results in compromised cartilage and disc integrity, increased inflammation, and chondrocyte apoptosis. The University of Washington Office of Sponsored Programs is the prime recipient. The award period of performance runs from September 1, 2026, through May 30, 2031, with work performed in Seattle, Washington.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $623.6k | 9/2/26 |